Objective To assess the efficacy and safety of Yiqi Yangyin Huoxue therapy (YYHT) for the treatment of IgA nephropathy. Methods Databases articles about YYHT in treating IgAN patients were searched through February 20...Objective To assess the efficacy and safety of Yiqi Yangyin Huoxue therapy (YYHT) for the treatment of IgA nephropathy. Methods Databases articles about YYHT in treating IgAN patients were searched through February 2018. Comparisons were YYHT alone or YYHT in combination with western medicine as experimental intervention, and western medicine as the control. Randomized controlled trials (RCTs) were selected. Cochrane collaboration tool was used for assessing risk of bias to evaluate methodologies. RevMan 5.3 software was applied to analyze the data of included trials. Results A total of 21 studies involving 1473 patients were included. Meta-analysis results demonstrated that YYHT alone or YYHT in combination with western medicine were more efficacious than only western medicine in decreasing proteinuria [MD =-0.41, 95% CI (-0.53,-0.29), P < 0.00001] and the urine red blood cells [MD =-7.46, 95% CI (-9.28,-5.64), P < 0.00001]. There also showed improvement in the clinical total effective rate [OR = 2.78, 95% CI (2.14, 3.61), P < 0.00001] between the two groups. Some of the included trials did not report the adverse events. Conclusions Current evidence shows that YYHT can reduce proteinuria and urine red blood cells and improve the total efficacy rate. Since poor quality and publication bias of some included trials, more evidence-based medicine studies needed to define the role of YYHT in the treatment of IgAN.展开更多
Objective:To systematically evaluate the effect of Yiqi Wenyang Huoxue therapy in treating diabetic kidney disease(DKD)of stage III-IV.Method:The relevant literature was retrieved by computer from CNKI,Wanfang and VIP...Objective:To systematically evaluate the effect of Yiqi Wenyang Huoxue therapy in treating diabetic kidney disease(DKD)of stage III-IV.Method:The relevant literature was retrieved by computer from CNKI,Wanfang and VIP databases,CBM,PubMed,EMBase,Cochrane Library and Web of Science.Articles screening and data extraction were performed by two researchers separately and independently.The Meta-analysis was conducted with RevMan 5.3.Results:A total of 10 randomized controlled trials were collected,including 778 cases with DKD.Meta-analysis showed that the Yiqi Wenyang Huoxue Method combined with western medicine basic treatment could reduce 24hUTP[MD=-0.36,95%CI(-0.46,-0.26),P<0.00001],UAER[MD=-36.72,95%CI(-47.21,-26.23),P<0.00001],Scr[MD=-16.28,95%CI(-20.59,-11.97),P<0.00001],BUN[MD=-1.45,95%CI(-1.76,-1.14),P<0.00001],TC[MD=-0.64,95%CI(-1.07,-0.21),P=0.004].There was also a reduction in HbA1c[MD=-0.50,95%CI(-0.94,-0.05),P=0.03],but the difference is not significant.Conclusion:Based on the current evidence,for the treatment of DKD of stage III-IV,basic western medicine treatment combined with Yiqi Wenyang Huoxue method may better reduce urine protein,total cholesterol levels and improve renal function.The conclusion of this study needs to be further researched by high-quality studies,because that the quality of the included studies is generally low.展开更多
AIM Study on the effects of Fuzheng Huoxue anticancer prescription (Traditional Chinese Medicine) in treating gastric cancer. METHODS Sixty nine patients with gastric cancer of mid or late stage were confirmed his...AIM Study on the effects of Fuzheng Huoxue anticancer prescription (Traditional Chinese Medicine) in treating gastric cancer. METHODS Sixty nine patients with gastric cancer of mid or late stage were confirmed histologically. They were divided into two groups. The treatment group included 35 cases (26 males and 9 females, 2 cases aged from 33～40 years, 18 from 41～60, 15 from 61～75, mean 58 4 years). The control group included 23 males and 11 females, 4 aged 33～40 years, 16 41～60, 14 61～75, averaging 56 8 years. The two groups were not significantly different in sex, age, clinical and pathological stages, operation mode, etc. The two group were given similar treatment. The treatment group was given Fuzheng Huoxue anticancer prescription. The cell line SGC 7901 was inoculated to the back of 30 nude mice under sterile condition. The nude mice were allocated randomly into control, traditional Chinese medicine and chemotherapeutic groups with 10 mice in each group with similar weight. Each nude mouse in control group received 0 5ml saline/day. The Fuzheng Huoxue anticancer prescreption was given to the traditional Chinese medicine group, 0 5ml/day (containing 1 5g crude drug) chamotherapentic group was injected with 1mg 5 Fu intraperitoneally once a week for 8 weeks. RESULTS Before treatment, OKT8 was 45 94±8 45%, OKT4/OKT8 was 0 89±0 19, AT Ⅲ was 29 9mg/dl±7 9mg/dl, Fa was 50 4%±24 4%, β TG was 91 0ng/dl±25 9ng/dl in treatment group; OKT8 was 49 21%±6 60%, OKT4/OKT8 was 0 94±0 20, AT Ⅲ was 32 3mg/dl±7 2mg/dl, Fa was 57 3%±24 6%, β TG was 87 5ng/dl±34 2ng/dl in controls before treatment. After treatment, OKT8 was 33 52%±7 80%, OKT4/OKT8 was 1 47±0 51, AT Ⅲ was 38 8mg/dl±5 5mg/dl, Fa was 102 6%±31 6%, β TG was 62 3ng/dl±15 1ng/dl in treatment group and OKT8 was 42 22%±7 07%, OKT4/OKT8 was 1 12±0 24, AT Ⅲ was 30 9mg/dl±8 0mg/dl, Fa was 64 6%±26 9%, β TG was 67 0ng/dl±42 1ng/dl in controls. After treatment, the T lymphocyte′s immunologic function of the patients with gastric cancer was significantly improved in the treatment group ( P <0 01). The hypercoagulability was improved ( P <0 001). OKT4/OKT8 ratio, antithrombin Ⅲ (AT Ⅲ), fibrinolytic activity, etc. were all normalized. The one year (86%), 3 year (69%) and 5 year (40%) suvival rates were increased as compared with controls, ( P <0 05). The mean tumor weighted 0 895g±0 289g in controls, 0 433g±0 177g in traditional Chinese medicine group and 0 357g±0 142g in chemotherapeutic group. The tumor inhibitory rates were 51 6% and 60 1% in traditional Chinese medicine group and chemotherapeutic group, respectively, significantly better than in the controls ( P <0 001). The mean tumor weight was 24 68±1 93g in traditional Chinese Medicine group, significantly higher than that in treatment group (22 96g±1 87g) and the controls (22 47g±2 18g). CONCLUSION Fuzheng Huoxue anticancer prescription can not only replenish vital fuction (Zheng qi), improve hypercoagulatory state, improve immunologic function and extend the survival of patient, but may also have direct inhibitory action on gastric tumor growth without side effects and toxicity.展开更多
文摘Objective To assess the efficacy and safety of Yiqi Yangyin Huoxue therapy (YYHT) for the treatment of IgA nephropathy. Methods Databases articles about YYHT in treating IgAN patients were searched through February 2018. Comparisons were YYHT alone or YYHT in combination with western medicine as experimental intervention, and western medicine as the control. Randomized controlled trials (RCTs) were selected. Cochrane collaboration tool was used for assessing risk of bias to evaluate methodologies. RevMan 5.3 software was applied to analyze the data of included trials. Results A total of 21 studies involving 1473 patients were included. Meta-analysis results demonstrated that YYHT alone or YYHT in combination with western medicine were more efficacious than only western medicine in decreasing proteinuria [MD =-0.41, 95% CI (-0.53,-0.29), P < 0.00001] and the urine red blood cells [MD =-7.46, 95% CI (-9.28,-5.64), P < 0.00001]. There also showed improvement in the clinical total effective rate [OR = 2.78, 95% CI (2.14, 3.61), P < 0.00001] between the two groups. Some of the included trials did not report the adverse events. Conclusions Current evidence shows that YYHT can reduce proteinuria and urine red blood cells and improve the total efficacy rate. Since poor quality and publication bias of some included trials, more evidence-based medicine studies needed to define the role of YYHT in the treatment of IgAN.
基金National Natural Science Foundation of China(No.81973801)。
文摘Objective:To systematically evaluate the effect of Yiqi Wenyang Huoxue therapy in treating diabetic kidney disease(DKD)of stage III-IV.Method:The relevant literature was retrieved by computer from CNKI,Wanfang and VIP databases,CBM,PubMed,EMBase,Cochrane Library and Web of Science.Articles screening and data extraction were performed by two researchers separately and independently.The Meta-analysis was conducted with RevMan 5.3.Results:A total of 10 randomized controlled trials were collected,including 778 cases with DKD.Meta-analysis showed that the Yiqi Wenyang Huoxue Method combined with western medicine basic treatment could reduce 24hUTP[MD=-0.36,95%CI(-0.46,-0.26),P<0.00001],UAER[MD=-36.72,95%CI(-47.21,-26.23),P<0.00001],Scr[MD=-16.28,95%CI(-20.59,-11.97),P<0.00001],BUN[MD=-1.45,95%CI(-1.76,-1.14),P<0.00001],TC[MD=-0.64,95%CI(-1.07,-0.21),P=0.004].There was also a reduction in HbA1c[MD=-0.50,95%CI(-0.94,-0.05),P=0.03],but the difference is not significant.Conclusion:Based on the current evidence,for the treatment of DKD of stage III-IV,basic western medicine treatment combined with Yiqi Wenyang Huoxue method may better reduce urine protein,total cholesterol levels and improve renal function.The conclusion of this study needs to be further researched by high-quality studies,because that the quality of the included studies is generally low.
文摘AIM Study on the effects of Fuzheng Huoxue anticancer prescription (Traditional Chinese Medicine) in treating gastric cancer. METHODS Sixty nine patients with gastric cancer of mid or late stage were confirmed histologically. They were divided into two groups. The treatment group included 35 cases (26 males and 9 females, 2 cases aged from 33～40 years, 18 from 41～60, 15 from 61～75, mean 58 4 years). The control group included 23 males and 11 females, 4 aged 33～40 years, 16 41～60, 14 61～75, averaging 56 8 years. The two groups were not significantly different in sex, age, clinical and pathological stages, operation mode, etc. The two group were given similar treatment. The treatment group was given Fuzheng Huoxue anticancer prescription. The cell line SGC 7901 was inoculated to the back of 30 nude mice under sterile condition. The nude mice were allocated randomly into control, traditional Chinese medicine and chemotherapeutic groups with 10 mice in each group with similar weight. Each nude mouse in control group received 0 5ml saline/day. The Fuzheng Huoxue anticancer prescreption was given to the traditional Chinese medicine group, 0 5ml/day (containing 1 5g crude drug) chamotherapentic group was injected with 1mg 5 Fu intraperitoneally once a week for 8 weeks. RESULTS Before treatment, OKT8 was 45 94±8 45%, OKT4/OKT8 was 0 89±0 19, AT Ⅲ was 29 9mg/dl±7 9mg/dl, Fa was 50 4%±24 4%, β TG was 91 0ng/dl±25 9ng/dl in treatment group; OKT8 was 49 21%±6 60%, OKT4/OKT8 was 0 94±0 20, AT Ⅲ was 32 3mg/dl±7 2mg/dl, Fa was 57 3%±24 6%, β TG was 87 5ng/dl±34 2ng/dl in controls before treatment. After treatment, OKT8 was 33 52%±7 80%, OKT4/OKT8 was 1 47±0 51, AT Ⅲ was 38 8mg/dl±5 5mg/dl, Fa was 102 6%±31 6%, β TG was 62 3ng/dl±15 1ng/dl in treatment group and OKT8 was 42 22%±7 07%, OKT4/OKT8 was 1 12±0 24, AT Ⅲ was 30 9mg/dl±8 0mg/dl, Fa was 64 6%±26 9%, β TG was 67 0ng/dl±42 1ng/dl in controls. After treatment, the T lymphocyte′s immunologic function of the patients with gastric cancer was significantly improved in the treatment group ( P <0 01). The hypercoagulability was improved ( P <0 001). OKT4/OKT8 ratio, antithrombin Ⅲ (AT Ⅲ), fibrinolytic activity, etc. were all normalized. The one year (86%), 3 year (69%) and 5 year (40%) suvival rates were increased as compared with controls, ( P <0 05). The mean tumor weighted 0 895g±0 289g in controls, 0 433g±0 177g in traditional Chinese medicine group and 0 357g±0 142g in chemotherapeutic group. The tumor inhibitory rates were 51 6% and 60 1% in traditional Chinese medicine group and chemotherapeutic group, respectively, significantly better than in the controls ( P <0 001). The mean tumor weight was 24 68±1 93g in traditional Chinese Medicine group, significantly higher than that in treatment group (22 96g±1 87g) and the controls (22 47g±2 18g). CONCLUSION Fuzheng Huoxue anticancer prescription can not only replenish vital fuction (Zheng qi), improve hypercoagulatory state, improve immunologic function and extend the survival of patient, but may also have direct inhibitory action on gastric tumor growth without side effects and toxicity.
